ES2307351B2 - Cepa viva atenuada de staphylococcus aureus como vacuna en mastitis de rumiantes. - Google Patents

Cepa viva atenuada de staphylococcus aureus como vacuna en mastitis de rumiantes. Download PDF

Info

Publication number: ES2307351B2
Authority: ES; Spain
Prior art keywords: strain; staphylococcus aureus; aureus; baselineskip; live
Prior art date: 2005-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

ES200500809A

Other languages

English (en)

Spanish (es)

Other versions

ES2307351A1 (es

Inventor

Ricardo De La Fuente Lopez

Gustavo Dominguez Bernal

Jose Antonio Orden Gutierrez

Susana Martinez Pulgarin

Jose Antonio Ruiz Santa-Quiteria

Dolores Cid Vazquez

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Universidad Complutense de Madrid

Original Assignee

Universidad Complutense de Madrid

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-07

Filing date

2005-04-07

Publication date

2009-06-17

2005-04-07 Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid

2005-04-07 Priority to ES200500809A priority Critical patent/ES2307351B2/es

2006-04-06 Priority to PCT/ES2006/000164 priority patent/WO2006106166A1/fr

2008-11-16 Publication of ES2307351A1 publication Critical patent/ES2307351A1/es

2009-06-17 Application granted granted Critical

2009-06-17 Publication of ES2307351B2 publication Critical patent/ES2307351B2/es

2025-04-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 22
241000282849 Ruminantia Species 0.000 title claims abstract description 11
208000004396 mastitis Diseases 0.000 title abstract description 10
230000002238 attenuated effect Effects 0.000 claims abstract description 21
241000191967 Staphylococcus aureus Species 0.000 claims abstract description 20
210000002919 epithelial cell Anatomy 0.000 claims abstract description 12
230000002688 persistence Effects 0.000 claims abstract description 10
230000003115 biocidal effect Effects 0.000 claims abstract description 7
230000035755 proliferation Effects 0.000 claims abstract description 7
101150115163 katA gene Proteins 0.000 claims description 29
238000012217 deletion Methods 0.000 claims description 28
230000037430 deletion Effects 0.000 claims description 28
101150028517 hlb gene Proteins 0.000 claims description 28
101100059196 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) katE gene Proteins 0.000 claims description 26
241001026509 Kata Species 0.000 claims description 26
101150013110 katG gene Proteins 0.000 claims description 26
101150108683 katG2 gene Proteins 0.000 claims description 26
241000894006 Bacteria Species 0.000 claims description 18
102000016938 Catalase Human genes 0.000 claims description 17
108010053835 Catalase Proteins 0.000 claims description 17
230000000694 effects Effects 0.000 claims description 11
101710124951 Phospholipase C Proteins 0.000 claims description 10
102000004190 Enzymes Human genes 0.000 claims description 5
108090000790 Enzymes Proteins 0.000 claims description 5
210000005075 mammary gland Anatomy 0.000 claims description 5
208000035473 Communicable disease Diseases 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
238000002255 vaccination Methods 0.000 claims description 4
239000000427 antigen Substances 0.000 claims description 3
108091007433 antigens Proteins 0.000 claims description 3
102000036639 antigens Human genes 0.000 claims description 3
230000006801 homologous recombination Effects 0.000 claims description 3
238000002744 homologous recombination Methods 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
238000010276 construction Methods 0.000 abstract description 6
230000035772 mutation Effects 0.000 abstract description 4
238000011160 research Methods 0.000 abstract description 2
230000002068 genetic effect Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 18
208000015181 infectious disease Diseases 0.000 description 16
239000013612 plasmid Substances 0.000 description 16
230000003834 intracellular effect Effects 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 11
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
239000002609 medium Substances 0.000 description 8
230000001018 virulence Effects 0.000 description 8
239000003053 toxin Substances 0.000 description 7
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
241000283690 Bos taurus Species 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
238000000540 analysis of variance Methods 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000000034 method Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
231100000765 toxin Toxicity 0.000 description 5
108700012359 toxins Proteins 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
229960003276 erythromycin Drugs 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000009545 invasion Effects 0.000 description 4
238000010172 mouse model Methods 0.000 description 4
230000008506 pathogenesis Effects 0.000 description 4
230000001717 pathogenic effect Effects 0.000 description 4
230000007918 pathogenicity Effects 0.000 description 4
238000013207 serial dilution Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
235000013365 dairy product Nutrition 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
231100000636 lethal dose Toxicity 0.000 description 3
244000005700 microbiome Species 0.000 description 3
210000001539 phagocyte Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 2
108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000007621 bhi medium Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
238000009650 gentamicin protection assay Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000008267 milk Substances 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
238000012552 review Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000009331 sowing Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
241001439211 Almeida Species 0.000 description 1
206010053555 Arthritis bacterial Diseases 0.000 description 1
241000589875 Campylobacter jejuni Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010065152 Coagulase Proteins 0.000 description 1
206010061788 Corneal infection Diseases 0.000 description 1
108010041986 DNA Vaccines Proteins 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
241000632511 Daviesia arborea Species 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
241000607473 Edwardsiella <enterobacteria> Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
241000589989 Helicobacter Species 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
108010006464 Hemolysin Proteins Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
235000019687 Lamb Nutrition 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000187678 Nocardia asteroides Species 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000158504 Rhodococcus hoagii Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000344863 Staphylococcus aureus subsp. aureus COL Species 0.000 description 1
101710145796 Staphylokinase Proteins 0.000 description 1
241000776233 Tisis Species 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000000680 avirulence Effects 0.000 description 1
210000003578 bacterial chromosome Anatomy 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
239000007382 columbia agar Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
239000003228 hemolysin Substances 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
229940124590 live attenuated vaccine Drugs 0.000 description 1
229940023012 live-attenuated vaccine Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000004783 oxidative metabolism Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
210000000680 phagosome Anatomy 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000000304 virulence factor Substances 0.000 description 1
230000007923 virulence factor Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
- C12R1/445—
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/44—Staphylococcus
- C12R2001/445—Staphylococcus aureus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ES200500809A 2005-04-07 2005-04-07 Cepa viva atenuada de staphylococcus aureus como vacuna en mastitis de rumiantes. Expired - Fee Related ES2307351B2 (es)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
ES200500809A ES2307351B2 (es)	2005-04-07	2005-04-07	Cepa viva atenuada de staphylococcus aureus como vacuna en mastitis de rumiantes.
PCT/ES2006/000164 WO2006106166A1 (fr)	2005-04-07	2006-04-06	Souche vive attenuee de staphylococcus aureus servant de vaccin contre la mammite bovine

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200500809A ES2307351B2 (es)	2005-04-07	2005-04-07	Cepa viva atenuada de staphylococcus aureus como vacuna en mastitis de rumiantes.

Publications (2)

Publication Number	Publication Date
ES2307351A1 ES2307351A1 (es)	2008-11-16
ES2307351B2 true ES2307351B2 (es)	2009-06-17

Family

ID=37073109

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES200500809A Expired - Fee Related ES2307351B2 (es)	2005-04-07	2005-04-07	Cepa viva atenuada de staphylococcus aureus como vacuna en mastitis de rumiantes.

Country Status (2)

Country	Link
ES (1)	ES2307351B2 (fr)
WO (1)	WO2006106166A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011027956A2 (fr) *	2009-09-04	2011-03-10	주식회사이언메딕스	Vésicules extracellulaires issues de bactéries à gram positif, et modèle de maladie utilisant celles-ci

2005
- 2005-04-07 ES ES200500809A patent/ES2307351B2/es not_active Expired - Fee Related
2006
- 2006-04-06 WO PCT/ES2006/000164 patent/WO2006106166A1/fr not_active Ceased

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAMLEY, A. J., PATEL, A. H., O'REILLY, M. et al. Roles of alpha- toxin and beta-toxin in virulence of Staphylococcus aureus for the mouse mammary gland. Infection and Immunity. Agosto 1989, Vol. 57, N$^{o}$ 8, páginas 2489-2494. ISSN 0019-9567. *
COLEMAN, D., KNIGHTS, J., RUSSELL, R. et al. Insertional inactivation of the Staphylococcus aureus beta-toxin by bacteriophage phi-13 occurs by site- and orientation-specific integration of the phi-13 genome. Molecular Microbiology. 1991, Vol. 5, N$^{o}$ 4, páginas 933-939. ISSN 0950-382X. *
ODIERNO, L., RISATTI, G., CALZOLARI, A. et al. Pathogenicity in mice of Staphylococcus aureus mutants deficient in exoprotein synthesis. Veterinary Microbiology. Agosto 1994, Vol. 41, N$^{o}$ 3 páginas 249-258. ISSN 0378-1135. *
SANZ, R., MARÍN, I., RUIZ-SANTA-QUITERIA, J. A. et al. Catalase deficiency in Staphylococcus aureus subsp. anaerobius is associated with natural loss-of-function mutations within the structural gene. Microbiology. Febrero 2000, Vol. 146, N$^{o}$ 2, páginas 465-475. ISSN 1350-0872. *

Also Published As

Publication number	Publication date
WO2006106166A1 (fr)	2006-10-12
ES2307351A1 (es)	2008-11-16

Publication	Publication Date	Title
Furuyama et al.	2021	Outer membrane vesicles (OMVs) produced by gram‐negative bacteria: structure, functions, biogenesis, and vaccine application
ES2237094T3 (es)	2005-07-16	Lactobacillus que albergan genes de agregacion celular y de fijacion de mucina, como vehiculos de aporte de vacunas.
Medina et al.	2003	Survival of Streptococcus pyogenes within host phagocytic cells: a pathogenic mechanism for persistence and systemic invasion
Kong et al.	2012	Phosphate groups of lipid A are essential for Salmonella enterica serovar Typhimurium virulence and affect innate and adaptive immunity
US8889121B2 (en)	2014-11-18	Bacterium comprising a regulated rfaH nucleic acid
Sarkar-Tyson et al.	2007	Polysaccharides and virulence of Burkholderia pseudomallei
Okan et al.	2010	The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection
US11707515B2 (en)	2023-07-25	Modified Brucella vaccine strain for the treatment of brucellosis
JP2016535766A (ja)	2016-11-17	弱毒化生ワクチン
PL204863B1 (pl)	2010-02-26	Zastosowanie mutanta Streptococcus, szczepionka i sposoby kontrolowania lub eliminowania choroby paciorkowcowej w populacji
Bandara et al.	2005	Carboxyl-terminal protease regulates Brucella suis morphology in culture and persistence in macrophages and mice
Kong et al.	2009	Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar Typhimurium vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen
Zhang et al.	2014	Deletion of the rfaE gene in Haemophilus parasuis SC096 strain attenuates serum resistance, adhesion and invasion
JP2001186874A (ja)	2001-07-10	サルモネラワクチン
Jiang et al.	2022	Preclinical evaluation of OMVs as potential vaccine candidates against Salmonella enterica serovar Enteritidis infection
Derakhshandeh et al.	2020	Surface display of uropathogenic Escherichia coli FimH in Lactococcus lactis: In vitro characterization of recombinant bacteria and its protectivity in animal model
Li et al.	2010	AatA is a novel autotransporter and virulence factor of avian pathogenic Escherichia coli
CN113329766A (zh)	2021-08-31	艰难梭菌多组分疫苗
Bandara et al.	2008	A disruption of ctpA encoding carboxy-terminal protease attenuates Burkholderia mallei and induces partial protection in CD1 mice
US20120082698A1 (en)	2012-04-05	Mutants of francisella tularensis and uses thereof
Vasilyeva et al.	2013	The role of membrane vesicles in secretion of Lysobacter sp. bacteriolytic enzymes
ES2307351B2 (es)	2009-06-17	Cepa viva atenuada de staphylococcus aureus como vacuna en mastitis de rumiantes.
JP4495143B2 (ja)	2010-06-30	生物学的安全性が向上した経口ワクチン接種用凍結乾燥形態のコレラ菌弱毒化株
Ramón Rocha et al.	2006	Membrane vesicles released by Avibacterium paragallinarum contain putative virulence factors
Bandara et al.	2005	Putative outer membrane autotransporter protein influences survival of Brucella suis in BALB/c mice

Legal Events

Date	Code	Title	Description
2008-11-16	EC2A	Search report published	Date of ref document: 20081116 Kind code of ref document: A1
2025-04-25	FD2A	Announcement of lapse in spain	Effective date: 20250425

Date

Code

Title

Description

2008-11-16

EC2A

Search report published

Date of ref document: 20081116

Kind code of ref document: A1

2025-04-25

FD2A

Announcement of lapse in spain

Effective date: 20250425